Camrelizumab Combined With Famitinib Malate and Chemotherapy for Treatment of Recurrent/ Metastatic Cervical Cancer (clinicaltrials.gov)

Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC (clinicaltrials.gov)

Targeting GPR34 in damage-associated macrophages enhances anti-tumor immunity and the efficacy of Surufatinib in pancreatic cancer. (PubMed, Signal Transduct Target Ther)

Efficacy and Safety of Surufatinib in Treating Pituitary Neuroendocrine Tumors: A Single-Center, Single-Arm, Exploratory Study (ChiCTR2600120740)

A Study to Evaluate the Efficacy and Safety of Cadonilimab Plus Famitinib in Combination With Chemotherapy for Advanced Ovarian Cancer (ChiCTR2600117773)

Analysis of Optimal Treatment Sequencing of Surufatinib and Somatostatin Analogs in Neuroendocrine Tumors: A Retrospective Cohort Study (clinicaltrials.gov)

Neoadjuvant SHR-1701 Plus Famitinib With Response-guided Adjuvant Therapy in Resectable Mucosal Melanoma (clinicaltrials.gov)

STARS-RC10: Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Without Concurrent Surufatinib in Neoadjuvant Therapy for Mid-to-low Localized Rectal Cancer of High-risk Criteria (clinicaltrials.gov)

Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer (clinicaltrials.gov)

A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Radical Resection of Cervical Cancer (clinicaltrials.gov)

Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer (clinicaltrials.gov)

Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer (clinicaltrials.gov)